Treatment of Moderate to Severe Glabellar Lines

Completed · Phase 3 · Has a placebo group

Conditions studied: Glabellar Frown Lines

In brief

The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.

Key facts

Study ID
NCT04249583
Run by
Galderma R&D
People needed
300
Starts
2020-02-10
Expected to finish
2021-01-05
Last updated by the study team
2023-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.